Victory Square Technologies Portfolio Company Receives Approval for Sale and Use of Safetest Covid-19 Antibody Test for the European Union

Victory Square Health received CE from EU competent authority of BelgiumA  for Safetest ELISA antibody test for distribution, sale, and usage in the European Union

Safetest Covid-19a?? test enables the user to verify whether they are currently infected, have been infected or have never been infected with Covid-19

This approval now enables Victory Square Health to distribute throughout the 27 countries and 446M inhabitants which make up the European Union

Victory Square Health received FDA permission to sell and market on August 14 and received Anvisa approval for Sale & Use of Safetest Covid-19 Antibody Test for the Country of Brazil on September 8.

VANCOUVER, British Columbia, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Victory Square Health Inc. (a??VS Healtha?? or the "Company") a?? a portfolio company of Victory Square Technologies Inc. ("Victory Square") (CSE:VST) (OTC:VSQTF) (FWB:6F6) announced today that it was granted EU declaration of conformity which indicates that a product complies with all the requirements of European IVDD (in-vitro diagnostic device) legislation. The CE designation allows the company to commenceA  marketing, sales and distribution for its Safetest ELISA Covid-19 assay for detecting the antibodies IgG and IgM against SARS-CoV-2, until May 2022.
VS Healtha??s Safetest Covid-19 IgG /IgM has demonstrated to the U.S. FDA & Brazilian authoritiesA  93.3%A  sensitivity and 98.7% specificity. As of September 10, 2020 the EU & EEA saw 2,476,000 Covid-19 cases and 183,479 deaths from Covid-19.The Company is focused on rapid production expansion combined with navigating key distribution channels and sales agreements in the European Union countries and beyond. The Company is actively pursuing additional manufacturing capabilities to meet the demand with approvals from countries in the EU, South America, the USA and beyond.A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A "Our ongoing mission is to help the global community curb the spread of Covid-19 by delivering the best tests in the market," said Felipe Peixoto, CEO of VS Health.A  a??This approval from the European Union now allows us to expand our sales and distribution reach of our Safetest suite of tests throughout the EU,a?? said Peixoto. Peixoto continued a??The Company will immediately look for manufacturing capabilities in the EU to meet the strong demand.a??The antibody data provided by VS Healtha??s Safetest Covid-19 IgM/IgG Elisa test kit covers both immunoglobulins type M (IgM) and G (IgG). When IgM antibodies are present, they can indicate that a patient has an active or recent infection with SARS-CoV-2. When IgG antibodies are present, it indicates past infection and exposure. The company has successfully completed the CE marking which indicates that a product has been assessed by the manufacturer and deemed to meet EU safety, health and environmental protection requirements. It is required for products manufactured anywhere in the world which are then marketed in the EU.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Октябрь 2020    »